Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of CUV-AX would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2001) — listing | $107,793 2.8× | $155,255 2.8× |
| Year 6 (2006) | $69,896 2.3× | $101,252 2.3× |
| Year 11 (2011) | $48,086 2.1× | $69,741 2.1× |
| Year 16 (2016) | $12,124 0.8× | $17,532 0.8× |
| Year 21 (2021) | $4,732 0.6× | $6,846 0.6× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Melbourne, Australia
Popular scenarios with CUV
For illustration only — not investment advice. Past performance is not indicative of future results.